ReviewCancers2024
Inorganic Nanomedicine-Mediated Ferroptosis: A Synergistic Approach to Combined Cancer Therapies and Immunotherapy.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Renaissance of Traditional Mineral Drugs in Cancer: Advanced Delivery Strategies and Bioengineering Approaches.Pharmaceutics · 2026Review
- Iron-Based Nanoparticles as Delivery Tools.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Ferroptosis-induced immune modulation: a new frontier in glioblastoma therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Review
- Bioengineering Strategies to Address Key Bottlenecks in Ferroptosis-Based Cancer Therapy: A Critical Review.International journal of nanomedicine · 2026Review
- Therapeutic targeting of cell death-immune crosstalk in cancer to rewire the tumor immune microenvironment.Molecular cancer · 2025Review
- Ferroptosis in AML: nanoparticles, biomarkers, and immune rewiring for therapeutic breakthroughs.Discover oncology · 2025Review
- Nanoparticle-Mediated Ferroptosis for Cancer Therapy: Mechanisms and Therapeutic Strategies.Nanotechnology, science and applications · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, has generated substantial interest in cancer therapy. Various methods have been developed to induce ferroptosis in tumor cells, including approved drugs, experimental compounds, and nanomedicine formulations. Unlike apoptosis, ferroptosis presents unique molecular and cellular features, representing a promising approach for cancers resistant to conventional treatments. Recent research indicates a strong link between ferroptosis and the tumor immune microenvironment, suggesting the potential of ferroptosis to trigger robust antitumor immune responses. Multiple cellular metabolic pathways control ferroptosis, including iron, lipid, and redox metabolism. Thus, understanding the interaction between tumor metabolism and ferroptosis is crucial for developing effective anticancer therapies. This review provides an in-depth discussion on combining inorganic nanoparticles with cancer therapies such as phototherapy, chemotherapy, radiotherapy, and immunotherapy, and the role of ferroptosis in these combination treatments. Furthermore, this paper explores the future of tumor treatment using nanomedicine, focusing on how inorganic nanoparticles can enhance ferroptosis in tumor cells and boost antitumor immunity. The goal is to advance ferroptosis-based nanomedicine from the laboratory to clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.